<DOC>
	<DOCNO>NCT00694135</DOCNO>
	<brief_summary>The purpose study define safe effective dose iontophoretic delivery dexamethasone phosphate ophthalmic solution use EyeGate® II Drug Delivery System patient non-infectious anterior segment uveitis .</brief_summary>
	<brief_title>Safety Efficacy Study Iontophoresis Dexamethasone Phosphate Treat Anterior Uveitis</brief_title>
	<detailed_description>This randomize , double-masked , parallel group , dose-comparison , exploratory study four dose iontophoretic delivery dexamethasone phosphate ophthalmic solution patient non-infectious anterior segment uveitis . The current study evaluate safety , tolerability , efficacy technology four dose level determine safe effective dose appropriate future trial .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis , Anterior</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>• Noninfectious anterior uveitis Uveitis infectious etiology Previous anterior uveitis episode ≤ 4 week prior baseline Intraocular pressure ( IOP ) ≥ 25 mmHg baseline , history glaucoma , and/or patient require ocular antihypertensive medication Topical corticosteroid treatment either eye &lt; 48 hour prior baseline Oral corticosteroid intraorbital corticosteroid treatment either eye &lt; 2 week prior baseline Active intermediate posterior uveitis</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Iontophoresis</keyword>
	<keyword>Non-Infectious Acute Anterior Segment Uveitis</keyword>
	<keyword>Ophthalmology</keyword>
</DOC>